

Importance of Differentiation of *Entamoeba Histolytica* from *Entamoeba Dispar*

Pages with reference to book, From 229 To 230

Rakhshanda Baqai (PMRC Research Centre, Jinnah Postgraduate Medical Centre, Karachi.)

Amoebiasis, caused by the protozoan parasite *Entamoeba Histolytica* has a world wide distribution. *Entamoeba* was recently reclassified as two species. *Entamoeba histolytica*, the commonest agent of invasive amoebiasis and *Entamoeba dispar*, a non-invasive commensal classified on the basis of biochemical, immunological and genetic evidence¹. *E. dispar* was described by E mile Brumpt in 1925 but dismissed as a synonym of *E. histolytica*. Later on in 1920 evidence indicated that previous finding may be correct and *E. dispar* is now accepted as a distinct species. The invasive form usually penetrate the mucosa resulting in massive destruction of host tissue and cause hemorrhagic colitis and extraintestinal abscess whereas the non-invasive form passively inhabits the cavities of the lower intestine as commensal². *E. dispar* has never been seen in an isolate from a patient with invasive disease but in rare cases pathogenic *E. histolytica* was observed from asymptomatic cases³. Signs of dysentery are more common in patients diagnosed with disease caused by species of *E. Histolytica*⁴. Current diagnosis of *E. histolytica* infection involves the direct microscopic identification of the parasite, a technique that is insensitive and cannot distinguish *E. histolytica* from *E. dispar*⁵. *E. histolytica* and *E. dispar* are morphologically identical but can be differentiated by various methods. Monoclonal antibodies are used to distinguish between *E. histolytica* and *E. dispar*. The common antigenic epitope of *E. histolytica* are on 150 KDA surface molecule and that mAb can distinguish between *E. histolytica* and *E. dispar*⁶. mAbs against galactose and Nacetyl galactosamine inhibitable adherence lectin to *E. histolytica* could be used to distinguish *E. dispar* from *E. histolytica*⁷. Isoenzyme analysis was also used to distinguish pathogenic from non-pathogenic species of *Entamoeba*⁸.

The reliability of PCR for the diagnosis of *E. histolytica* infection has been shown in several studies^{9,10}. Development of a simple and reliable method to distinguish *E. histolytica* from *E. dispar* by using DNA for diagnosis would be of utmost importance¹¹. PCR has become an integral part of a sensitive and specific diagnostic strategy^{12,13}. PCR was also compared with isoenzyme analysis and the Tech Lab *E. histolytica* specific antigen detection test. PCR was based on amplification of small subunit ribosomal RNA gene of *E. histolytica* and *E. dispar* followed by restrictive digest analysis of the PCR product. PCR was 87% (46/53) and antigen detection 85% (45/53) sensitive. Mixed infection with *E. histolytica* and *E. dispar* were detected by PCR in 14% (12/88)¹⁴. PCR reaction was used to detect amoebiasis in 804 individuals using formalin fixed stools. Twenty-one stools (2.6 1%) contained *E. dispar* and 3 (0.373%) stools contained *E. histolytica*. Mixed infection of *E. dispar* with other parasites was also observed. Co-infection of *E. histolytica* with *E. dispar* was not observed¹⁵.

Specific DNA sequences have subsequently been identified and used as probes for the detection of pathogenic and non-pathogenic species¹⁶.

Antigen detection test for *E. histolytica* and *E. dispar* is more sensitive and specific than microscopy and is more reliable and rapid than zymoderne analysis for the differentiation of *E. histolytica* and *E. dispar*⁴.

All three techniques for specific identification of *E. histolytica* showed excellent correlation. Tech Lab *E. histolytica* antigen detection test was both rapid and technically simple¹⁴.

Amoebiasis can be prevented and controlled by measures like improving water supply, excreta disposal and food safety, health education and general social and economic development.

As amoebiasis is common in our population it is advisable that proper identification is done for both the pathogenic and non pathogenic amoeba so that treatment is only given if pathogenic *E. histolytica* is identified and indiscriminate use of drug is avoided which will lead to resistance to various drugs.

References

1. Diamond LS, Clark CO. A redescription of *Entamoeba histolytica*, Schaudinn, 1903, Emended Walker, 1911 separating it from *Entamoeba dispar* Brumpt, 1925, J. Euk. Microbiol., 1993~40:340-44.
2. Leppie M, Bahr E, Tannich E, et al. Comparison of preforming peptides from pathogenic and non pathogenic *Entamoeba histolytica*. Mol. Biochem. Parasitol., 1993~59:101-10.
3. Strachen WP, Chiondino PL, Spice WM, et al. Immunological differentiation of pathogenic and non-pathogenic isolates of *Entamoeba histolytica*. Lancet, 1988;1:561-63.
4. Haque R, Nevilli LM, Hahn P, et al. Rapid diagnosis of *Entamoeba histolytica* by using *Entamoeba* and *Entamoeba histolytica* stool antigen detection kit. J. Clin. Microbiol., 1995;33:2558-61.
5. Haque R, Nevilli LM, Wood S. et al. Detection of *Entamoeba histolytica* and *Entamoeba dispar* directly in stools. Am. J. Trop. Med. Hyg., 1994;50:594-96.
6. Tachibana H, Kobayashi S, Chang XJ, et al. Differentiation of *Entamoeba histolytica* and *Entamoeba dispar* facilitated by monoclonal antibody against a 150 KDA surface antigen. Parasitol. Res., 1997;83:435-39.
7. Haque R, Kress K, Wood S, et al. Diagnosis of pathogenic *Entamoeba histolytica* infection using a stool ELISA based on monoclonal antibodies to the galactose specific adhesion. J. Infect. Dis., 1993;167:247-49.
8. Sarqunt PG, William JE, Grene JO. The differentiation of invasive and non-invasive *Entamoeba histolytica* by isoenzyme electrophoresis. Trans. R. Soc. Trop. Med. Hyg., 1978;75:519-21.
9. Tachibana H, Kabyastri S, Takekoshi M, et al. Distinguishing pathogenic isolates of *Entamoeba histolytica* by polymerase chain reaction. J. Infect. Dis., 1991;164:825-26
10. Acuna SR, Samuelson J, De Girolani P, et al. Application of the polymerase chain reaction to the epidemiology of pathogenic and non-pathogenic *Entamoeba histolytica*. Am. J. Trop. Med. Hyg., 1993;48:59-70.
11. Riveria W, Tachibana H, Agnes MR, et al. Differentiation of *Entamoeba histolytica* and *Entamoeba dispar* DNA from cysts present in stool specimen by polymerase chain reaction; its field application in the Phillipines. Parasitol. Res., 1996;82:585-89.
12. Riveria WL, Tachibana H, Kanabara Field study on the distribution of *Entamoeba histolytica* and *Entamoeba dispar* in the northern Phillipines as detected by Polymerase chain reaction. Am. J. Trop. Med. Hyg., 1998;59:916-21.
13. Gonzalez RA, Haque R, Rebman T, et al. A monoclonal antibody for detection of invasive and non-invasive clinical isolates of *Entamoeba histolytica*. J. Clin. Micro., 1992;30:2807-13
14. Petri WA, Haque R. Distinguishing pathogenic *Entamoeba* from non pathogenic *E. dispar*. Abstract SE 12-I Ninth International congress of Parasitology ICOPA IX Aug., 1998, Chiba, Japan.
15. Riveria WL, Riveria PT, Vilacone EA, et al. *Entamoeba histolytica* and *Entamoeba dispar* detection by the polymerase chain reaction in a low prevalence region in the Phillipines. Abstract No 0 0214 Ninth International Congress of Parasitology, ICOPA IX, August, 1998.
16. Garfinkel LI, Gilagi M, Huber M, et al. DNA probe specific for *Entamoeba histolytica* possessing pathogenic and non-pathogenic zymodemes Infec. Immun., 1989;57:926-31.